Search research articles
Contact Us
Filters
Showing results (1-10 of 90) with videos related to
Page
of 9
Sort By:
The American Journal of Cardiology
|
June 5, 2003
How cost-effective are new preventive strategies for cardiovascular disease?
Jeffrey L Probstfield
The American Journal of Cardiology
|
January 28, 2010
Introduction. The cardiovascular continuum in the 21st century: renin-angiotensin system blockade, the cardiovascular continuum in the 21st century
Jeffrey L Probstfield, Michael A Weber
JAMA
|
October 27, 2011
Strategies for recruitment and retention of participants in clinical trials
Jeffrey L Probstfield, Robert L Frye
The American Journal of Cardiology
|
January 28, 2010
Progression of cardiovascular damage: the role of renin-angiotensin system blockade
Jeffrey L Probstfield, Kevin D O'Brien
The New England Journal of Medicine
|
March 30, 2026
Paving the Road toward Targeted Lipid Lowering
Jeffrey L Probstfield, Kelley R H Branch
The New England Journal of Medicine
|
March 17, 2016
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome
Marc A Pfeffer, Brian Claggett, Jeffrey L Probstfield
European Journal of Heart Failure
|
October 12, 2022
Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'
Kelley R H Branch, Hertzel C Gerstein, Jeffrey L Probstfield
Diabetes Care
|
September 24, 2016
Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973-981
Kevin D O'Brien, Irl B Hirsch, Matthew C Riddle, et al.
American Heart Journal
|
June 23, 2007
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND)
Michael Böhm, Magnus Baumhäkel, Jeffrey L Probstfield, et al.
The American Journal of Cardiology
|
January 28, 2010
Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA])
Pathmaja Paramsothy, Ronit Katz, David S Owens, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 90) with videos related to
Sort By:
Page
of 9
The American Journal of Cardiology
|
June 5, 2003
How cost-effective are new preventive strategies for cardiovascular disease?
Jeffrey L Probstfield
The American Journal of Cardiology
|
January 28, 2010
Introduction. The cardiovascular continuum in the 21st century: renin-angiotensin system blockade, the cardiovascular continuum in the 21st century
Jeffrey L Probstfield, Michael A Weber
JAMA
|
October 27, 2011
Strategies for recruitment and retention of participants in clinical trials
Jeffrey L Probstfield, Robert L Frye
The American Journal of Cardiology
|
January 28, 2010
Progression of cardiovascular damage: the role of renin-angiotensin system blockade
Jeffrey L Probstfield, Kevin D O'Brien
The New England Journal of Medicine
|
March 30, 2026
Paving the Road toward Targeted Lipid Lowering
Jeffrey L Probstfield, Kelley R H Branch
The New England Journal of Medicine
|
March 17, 2016
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome
Marc A Pfeffer, Brian Claggett, Jeffrey L Probstfield
European Journal of Heart Failure
|
October 12, 2022
Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'
Kelley R H Branch, Hertzel C Gerstein, Jeffrey L Probstfield
Diabetes Care
|
September 24, 2016
Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973-981
Kevin D O'Brien, Irl B Hirsch, Matthew C Riddle, et al.
American Heart Journal
|
June 23, 2007
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND)
Michael Böhm, Magnus Baumhäkel, Jeffrey L Probstfield, et al.
The American Journal of Cardiology
|
January 28, 2010
Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA])
Pathmaja Paramsothy, Ronit Katz, David S Owens, et al.
Page
of 9